Apellis Pharmaceuticals (APLS) PT Lowered to $38 at Mizuho
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Citi Reiterates Buy Rating on Apellis Pharmaceuticals (APLS)
October 28, 2024 5:42 AM EDTCiti analyst Yigal Nochomovitz reiterated a Buy rating and $63.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS).
The analyst comments "At ASN, APLS shared additional Ph3 data for pegcetacoplan in C3G/IC-MPGN, reiterating an overall proteinuria reduction of ~68% and clinically meaningful proteinuria... More
